AB-FUBINACA
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
AB-FUBINACA is a synthetic cannabinoid of the indazole-3-carboxamide class. It is among the most potent synthetic cannabinoids characterized, far exceeding the receptor activity of cannabis. AB-FUBINACA is a full agonist at CB1 cannabinoid receptors,[1] producing its effects by overriding the brain's endocannabinoid signaling with tonic activation.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized by Pfizer in 2009 as a candidate analgesic, the compound was never advanced to clinical development.[2] It first appeared in illicit herbal smoking blends in Japan in 2012[3] and spread rapidly through global research chemical markets. AB-FUBINACA was permanently placed into US DEA Schedule I in 2016 and is now controlled in most major jurisdictions.
Subjective effects include sedation, cognitive impairment, confusion, hallucinations, and agitation.[4] The experience is intense and compressed — a rapid smoked onset gives way to heavy, disorienting cannabinoid effects that lack the self-limiting ceiling characteristic of cannabis.[5] Cardiovascular disturbance, acute psychological distress, and severe confusion are characteristic unsought effects.[6]
AB-FUBINACA produces physical dependence in animal models,[5] and no lethal dose has been established in any species. Full agonism removes the ceiling on CB1 activation, and unusually slow clearance prolongs exposure;[7] chronic dosing in mice causes brain damage, kidney injury, and reproductive toxicity.[8][9][10] No controlled human studies exist — the evidence base rests on animal pharmacology, forensic casework, and clinical toxicology reports.
History[edit]
Discovery
AB-FUBINACA was synthesized by Pfizer in 2009 as part of a research program targeting cannabinoid receptor agonists for pain management. The compound was disclosed in international patent WO2009/106982,[1] which described a series of indazole-3-carboxamide derivatives bearing the L-valinamide side chain. It was never advanced to preclinical development or human testing.
Illicit emergence and scheduling
AB-FUBINACA first surfaced in illicit herbal smoking blends seized in Japan in 2012, identified by researchers at the National Institute of Health Sciences in Tokyo.[3] Japan responded within months, becoming the first country to schedule the compound in December 2012. The compound then proliferated across European, North American, and Asian markets, prompting a wave of international scheduling that included US DEA temporary Schedule I placement in early 2014 and permanent scheduling in September 2016.[2]
Present status
AB-FUBINACA is now controlled in most major jurisdictions and was placed into Schedule II of the 1971 UN Convention on Psychotropic Substances in 2020.[11] Its scheduling contributed to market displacement toward newer, unscheduled synthetic cannabinoid analogs — continuing the cyclical pattern of prohibition followed by structural modification to evade controls.
The name AB-FUBINACA follows synthetic cannabinoid naming conventions: AB denotes the amino acid side chain (from L-valine), FUB refers to the 4-fluorobenzyl substituent, and INACA indicates the indazole-carboxamide scaffold.
Chemistry[edit]
Structural class
AB-FUBINACA belongs to the indazole-3-carboxamide family of synthetic cannabinoid receptor agonists. Its structure consists of a 1H-indazole core with a 4-fluorobenzyl group at the N-1 position and an L-valinamide chain at the 3-carboxamide position.[1] This architecture places it alongside several related compounds: AB-PINACA (pentyl instead of fluorobenzyl), ADB-FUBINACA (tert-leucinamide instead of valinamide), and AMB-FUBINACA (methyl ester instead of primary amide).
The fluorine atom at the para position of the benzyl ring contributes to metabolic stability — no metabolic modifications on the fluorobenzyl side chain were observed in human liver microsome studies.[13]
Molecular properties
| Molecular formula | C₂₀H₂₁FN₄O₂ |
| Molecular weight | 368.4 g/mol |
Stereochemistry
AB-FUBINACA has one chirality center at the valinamide side chain, producing (S)- and (R)-enantiomers. The pharmacologically active form is the (S)-enantiomer, derived from L-valine, which shows significantly greater potency at both CB1 and CB2 receptors than the (R)-form.[14]
Illicit products contain predominantly the (S)-enantiomer (over 93% enantiomeric excess in seized samples), consistent with synthesis from commercially available L-valine.[14] The two enantiomers also differ sharply in clearance rate — the active (S)-form is eliminated far more slowly by the liver.[15]
Six positional isomers have been characterized, including 2H-indazole variants that may arise as manufacturing impurities during clandestine synthesis.[16] These retain cannabinoid activity but at lower potency than the correct 1H-indazole form.[16]
Pharmacology[edit]
Mechanism of action
AB-FUBINACA is a full agonist at cannabinoid CB1 and CB2 receptors, with strong selectivity for CB1.[1] This distinguishes it from cannabis's active compound Δ9-THC, which is a partial agonist with a built-in ceiling on CB1 activation. AB-FUBINACA bypasses that ceiling entirely, producing more intense effects across the dose range.
The primary signaling pathway proceeds through Gi/o proteins, which suppress the cell's production of the messenger molecule cAMP. In potency comparisons for this pathway, AB-FUBINACA exceeds JWH-018 and XLR-11.[17]
AB-FUBINACA also activates potassium channels (GIRK) through CB1,[18] but unlike some other synthetic cannabinoids, it does not significantly activate TRPV1 pain-sensing channels — indicating a cleaner CB1-selective signaling profile.[18]
In rats, AB-FUBINACA produces dose-dependent drops in body temperature and heart rate at 0.3–3 mg/kg. Both effects are fully reversed by the CB1 blocker rimonabant but not by a CB2 blocker, confirming that CB1 alone mediates its cannabinoid effects.[19]
Pharmacokinetics
No controlled human pharmacokinetic study has been published. Available data come from laboratory microsome studies, one controlled oral administration case, and forensic urine monitoring.
AB-FUBINACA resists liver breakdown more than most synthetic cannabinoids — after three hours with human liver microsomes, 77% of the parent compound remained intact.[13] The active (S)-enantiomer is cleared approximately 40 times more slowly than the inactive (R)-form,[15] suggesting prolonged exposure to the pharmacologically active compound.
Urinary elimination is extraordinarily prolonged. In a heavy user undergoing monitored abstinence, metabolites were detectable in every urine sample collected over a two-year period — an elimination phase potentially exceeding one year after last use.[7] This extended window confounds abstinence monitoring in addiction treatment settings.
Fifteen urinary metabolites have been identified.[13] Primary pathways include hydroxylation on the indazole ring and valinamide chain, dealkylation, and amide hydrolysis. Parent AB-FUBINACA was detectable in 54% of urine samples — unusually high for synthetic cannabinoids, consistent with the compound's slow clearance.[13]
Neuroscience[edit]
Where it acts
AB-FUBINACA engages CB1 receptors on presynaptic nerve terminals throughout the brain, where these receptors normally function as part of a feedback system — endocannabinoids are released on demand by receiving neurons to dial down neurotransmitter release. Full exogenous agonists override this demand-driven architecture by keeping CB1 tonically activated regardless of synaptic need, disrupting the brain's homeostatic signaling.
In the hippocampus, chronic exposure in mice produces measurable damage: increased oxidative stress, neuroinflammation, elevated cell death, reduced BDNF (a growth factor critical for learning and memory), and decreased NMDA expression.[8] These changes are accompanied by recognition memory suppression.
Why it matters
The NMDA receptor downregulation observed in chronically exposed mice[8] connects AB-FUBINACA to the glutamate hypothesis of psychosis — reduced NMDA signaling is one of the leading models for how schizophrenia-spectrum symptoms arise. Full CB1 agonists also facilitate dopamine release in the brain's mesolimbic pathway more strongly than partial agonists, potentially explaining why synthetic cannabinoid dependence develops more readily than cannabis dependence.
The bidirectional cardiovascular response — fast heart rate in some patients,[6] slow heart rate and low blood pressure in others[20] — likely reflects dose-dependent shifts in autonomic nervous system balance. In rats, the slowing response predominates and scales with dose.[19]
- Does the hippocampal NMDA receptor downregulation seen in mice[8] translate to psychosis vulnerability in humans? No longitudinal study has tracked psychosis incidence in AB-FUBINACA-exposed populations.
- Is the extraordinarily prolonged urinary retention[7] pharmacologically meaningful — does tissue-stored compound maintain low-level CB1 activation during the extended elimination phase, or is the retained material inert?
Subjective Effects[edit]
AB-FUBINACA delivers a cannabinoid experience defined by its intensity and brevity. Smoked administration produces near-immediate onset followed by a dense, heavy alteration of consciousness — sedation, cognitive fog, and perceptual distortion compressed into a short window. The experience is highly sensitive to dose and individual factors: identical exposures have produced drowsy calm in some people and severe agitation with hallucinations in others.[4] Set and setting modulate the psychological tone substantially.
Relative to cannabis, AB-FUBINACA occupies a fundamentally different pharmacological position. Where Δ9-THC's partial agonism produces self-limiting effects, AB-FUBINACA's full agonism removes that ceiling — placing its intensity and risk profile closer to potent synthetic cannabinoids like JWH-018 and 5F-MDMB-PICA than to cannabis, despite sharing the same receptor target.
Effect Grid
The full cannabimimetic profile manifests — sedation dominates, accompanied by pronounced thought deceleration, analysis suppression, and cognitive impairment. Immersion enhancement and conceptual thinking may emerge. Anxiety and paranoia are possible, particularly in unfamiliar settings or anxious individuals. Spontaneous body sensations and vestibular distortion contribute to a notable altered state.
Physical effects include marked bodily heaviness, motor control impairment, dry mouth, appetite enhancement, and nausea in some users. Cardiovascular effects become possible — heart rate changes in either direction (tachycardia or bradycardia) may occur unpredictably.
Duration spans approximately 1–2 hours total. This is a full agonist with no ceiling effect — the dose-response curve is steeper and less forgiving than cannabis.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Proprioceptive distortion · Visual acuity suppression · Visual haze / noise · Color enhancement · Perspective distortion · Sound sensitivity · Taste enhancement · Touch enhancement · Brightness alteration · Color alteration · Auditory distortion · Auditory misinterpretation · Geometry · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations · Visual recursion
Color enhancement · Perspective distortion · Sound sensitivity · Taste enhancement · Touch enhancement · Brightness alteration · Color alteration · Auditory distortion · Auditory misinterpretation · Geometry · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations · Visual recursion
Bodily heaviness · Dizziness · Heart rate perception changes · Physical fatigue · Appetite enhancement · Spontaneous body sensations · Muscle relaxation · Dehydration sensation · Laughter fits · Tactile euphoria · Nausea · Pain suppression · Breathing alteration · Constipation · Excessive sweating · Headache · Restlessness · Trembling · Vomiting · Involuntary body movements · Nausea suppression
Appetite enhancement · Spontaneous body sensations · Muscle relaxation · Dehydration sensation · Laughter fits · Tactile euphoria · Nausea · Pain suppression · Breathing alteration · Constipation · Excessive sweating · Headache · Restlessness · Trembling · Vomiting · Involuntary body movements · Nausea suppression
Analysis suppression · Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Immersion enhancement · Memory fragmentation · Thought disorganization · Thought connectivity · Aesthetic enhancement · Cognitive dysphoria · Cognitive euphoria · Language suppression · Motivation suppression · Novelty enhancement · Humor enhancement · Conceptual thinking · Pattern recognition enhancement · Thought loops · Creativity enhancement · Amnesia · Delusions · Delirium
Focus suppression · Information processing suppression · Immersion enhancement · Memory fragmentation · Thought disorganization · Thought connectivity · Aesthetic enhancement · Cognitive dysphoria · Cognitive euphoria · Language suppression · Motivation suppression · Novelty enhancement · Humor enhancement · Conceptual thinking · Pattern recognition enhancement · Thought loops · Creativity enhancement · Delusions · Delirium
Dysphoria · Irritability · Anxiety suppression
Sociability suppression · Craving · Disinhibition · Sociability enhancement · Cognitive disconnection
Cognitive disconnection
Timeline
Rapid absorption via pulmonary route; effects emerge within seconds to minutes. Initial body sensation changes and a cognitive shift begin. First alerts of altered sensorium are typically felt within the first few minutes.
Maximum intensity — sedation, cognitive impairment, bodily heaviness, and cardiovascular effects reach their strongest. Anxiety, paranoia, and perceptual disturbances are most likely during this phase. Full agonist pharmacology means no ceiling on intensity.
Relatively rapid decline in subjective effects. Sedation begins to lift and cognitive function starts to return. Motor impairment and mild cognitive fog may linger beyond the perceived end of the peak.
Residual sedation and mild cognitive fog. Most acute effects have resolved. Appetite changes may persist.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 1.5 weeks
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- cannabinoids
Toxicity
No lethal dose for AB-FUBINACA has been established in any species. No controlled dose-escalation study has been conducted in humans. The toxic threshold is unknown.
Acute toxicity
Acute intoxication presents as altered consciousness, agitation, drowsiness, hallucinations, and cognitive impairment.[4] Cardiovascular effects are unpredictable in direction: rapid heart rhythm has been documented in a case involving AB-FUBINACA and ADB-FUBINACA,[6] while slow heart rate and low blood pressure appeared in separate case series.[20]
At least one fatality has been documented in forensic investigation, involving AB-FUBINACA combined with the synthetic opioid U-47700.[21] The relative contribution of each substance remains unresolved.
AB-FUBINACA has been detected as an adulterant in unregulated drug supplies, including products not sold as synthetic cannabinoids.[22] Users of other substances may be exposed unknowingly. The combination with opioids is particularly dangerous given documented fatality data.[21]
Brain toxicity
Chronic administration in mice produces damage to memory-related brain regions: increased oxidative stress, inflammation, elevated cell death, and impaired memory function.[8] No human brain imaging or tissue data exist.
Kidney toxicity
Mouse studies demonstrate kidney damage consistent with acute kidney injury.[9] Acute kidney injury has been reported in human users of the broader synthetic cannabinoid class,[23] though no AB-FUBINACA-specific human case has been published.
Reproductive toxicity
Subacute exposure in mice impairs male fertility and causes testicular tissue damage.[10] No human reproductive data exist.
DNA damage
AB-FUBINACA causes DNA damage in cultured human white blood cells at laboratory-relevant concentrations.[24] Two structurally related compounds (AMB-FUBINACA, EMB-FUBINACA) showed similar effects.[24] Laboratory DNA damage does not necessarily predict cancer risk but warrants caution regarding long-term exposure.
Psychological Risks
Acute psychological disturbance is a consistent feature of synthetic cannabinoid intoxication. Presentations include confusion, agitation, hallucinations, delusions, and severely impaired reality testing.[4][6] These effects exceed those expected from cannabis because full CB1 agonists bypass the ceiling on psychotomimetic effects that partial agonists impose.
High-potency CB1 full agonists carry elevated psychosis risk compared to cannabis.[25] Whether AB-FUBINACA causes persistent psychotic symptoms or triggers psychotic disorders in vulnerable individuals has not been studied. The NMDA changes observed in chronically exposed mice[8] provide a plausible biological mechanism but do not establish causation in humans.
Tolerance and Dependence
Physical dependence develops in mice with repeated dosing, demonstrated through precipitated withdrawal.[5] This is consistent with the general pattern for high-potency CB1 full agonists, which downregulate and desensitize receptors more readily than partial agonists.
Tolerance develops with prolonged use. Cross-tolerance to other cannabinoids — both synthetic and plant-derived — is expected based on the shared CB1 mechanism. The synthetic cannabinoid class as a whole demonstrates higher abuse potential than cannabis due to full agonism and greater potency.[5]
The extraordinarily prolonged urinary detection window — potentially exceeding one year in heavy users[7] — means urine drug screens cannot reliably distinguish recent use from residual elimination in former heavy users.
Drug Interactions
No controlled interaction studies have been published. Available data derive from case reports and pharmacological reasoning.
Opioids represent the most clearly documented hazard. A fatality involving AB-FUBINACA combined with U-47700 has been documented.[21] The combination produces additive nervous system and breathing depression. AB-FUBINACA has appeared as an adulterant in unregulated supplies,[22] meaning opioid users may be exposed without knowledge.
Cannabis and other CB1 agonists produce additive receptor activation. Co-use potentiates sedation, cognitive impairment, cardiovascular effects, and psychosis risk.
Sedatives (benzodiazepines, alcohol, barbiturates) are expected to produce additive sedation and breathing depression. No AB-FUBINACA-specific data exist for these combinations.
CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) may increase AB-FUBINACA blood levels by slowing liver clearance. CYP3A4 inducers (rifampicin, carbamazepine, St. John's Wort) may accelerate clearance. Both interactions are inferred from structural analogy and have not been clinically evaluated.[26] inferred
Contraindications
Heart rhythm disorders or structural heart disease — rapid heart rhythm has been documented during AB-FUBINACA exposure,[6] and the direction of cardiovascular response is unpredictable.
Psychotic disorders or high psychosis risk — all high-potency CB1 full agonists carry elevated psychosis risk compared to cannabis.[25] Personal or family history of psychotic disorders is an absolute contraindication.
Kidney disease — animal data demonstrate kidney toxicity,[9] and the broader synthetic cannabinoid class is associated with acute kidney injury in humans.[23]
Pregnancy and breastfeeding — no human reproductive safety data exist. Animal studies show male reproductive toxicity,[10] and DNA damage has been demonstrated in human cell cultures.[24]
Concurrent opioid use — documented fatality from the combination.[21]
Harm Reduction[edit]
Forms & Identification
AB-FUBINACA typically appears in herbal smoking blends where dried plant material is sprayed with a solution of the compound. The concentration varies dramatically between and within products — hotspots of concentrated material on a single leaf can deliver a dose many times higher than adjacent material from the same package. Standard immunoassay cannabis drug tests may not detect synthetic cannabinoids; specialized SCRA panels or laboratory mass spectrometry are required for confirmation.
Guidelines
- Test all material with reagent kits and, where available, laboratory drug checking services — visual inspection cannot distinguish AB-FUBINACA from other synthetic cannabinoids or herbal blends.
- Start with the smallest possible amount. Hotspot distribution in sprayed herbal products means no two portions from the same batch are equivalent.
- Have a sober, trusted person present who knows what was taken and can call for help if needed.
- Do not redose during the active window. The short duration creates an compulsive redosing urge that can rapidly produce toxicity.
- Keep the environment calm, quiet, and temperature-controlled — AB-FUBINACA affects body temperature regulation.
- Do not use alone. Loss of consciousness and cardiovascular events have been documented with synthetic cannabinoids.
Set & Setting
The compressed duration and unpredictable intensity of AB-FUBINACA make environment critical. A familiar, physically safe indoor space with a sober companion present is the minimum reasonable precaution. The rapid onset via smoking means there is minimal time to adjust once the experience begins — avoid situations requiring coordination, driving, or complex decision-making.
Aftercare & integration. The short active duration of AB-FUBINACA can leave users feeling disoriented or anxious in the hours following exposure. Rest in a calm environment, eat when appetite returns, and hydrate. Avoid driving or operating machinery for at least several hours after effects resolve.
If the experience involved psychological distress — confusion, hallucinations, panic — it may help to talk through the experience with a trusted person. Persistent anxiety, paranoia, or perceptual disturbances lasting more than 24 hours warrant professional evaluation.
Recovery & Support
Synthetic cannabinoid dependence is a recognized clinical condition with withdrawal symptoms that may include irritability, sleep disruption, appetite suppression, and anxiety. The prolonged urinary elimination of AB-FUBINACA complicates monitoring — positive urine tests may reflect past heavy use rather than relapse.[7]
Professional support options include addiction medicine specialists familiar with synthetic cannabinoids, cognitive behavioral therapy, and peer support groups. SAMHSA's National Helpline (1-800-662-4357) provides free referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Unresponsiveness, seizure, chest pain, breathing difficulty, blue-tinged lips or fingers, extreme agitation with self-harm risk, or collapse. These distinguish a medical emergency from an uncomfortable but self-resolving experience.
- 1. Call emergency services immediately if any of the above signs appear.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. Do not leave the person alone. Monitor breathing continuously.
- 4. Do not restrain an agitated person unless they are in immediate physical danger — restraint can worsen cardiovascular stress.
- 5. If the person stops breathing, begin CPR if trained.
What to tell the dispatcher: The substance taken (synthetic cannabinoid or AB-FUBINACA if known), approximate amount and time, current symptoms, and whether other substances were involved. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent for synthetic cannabinoid intoxication exists. Treatment is supportive.
Legal Status[edit]
AB-FUBINACA is broadly controlled across major jurisdictions. It was one of the earliest indazole-3-carboxamide synthetic cannabinoids to be specifically scheduled, beginning with Japan in December 2012 — the same year it was first detected in illicit products.[3] Internationally, it was placed into Schedule II of the 1971 UN Convention on Psychotropic Substances in 2020,[11] obligating signatory nations to implement controls.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary scheduling January 2014; permanent placement September 6, 2016 (81 FR 61498)[2] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under third-generation SCRA generic definition, effective December 14, 2016citation needed |
| Germany | Anlage II (Narcotics Act) | Scheduled November 2014citation needed |
| Japan | Designated Substance (Pharmaceutical and Medical Device Act) | First jurisdiction to schedule; December 2012[3] |
| China | Controlled substance | Effective October 2015citation needed |
| Finland | Banned (government decree on psychoactive substances) | Effective October 19, 2017citation needed |
| International (UN) | Schedule II, 1971 Convention on Psychotropic Substances | Placed 2020[11] |
| Canada | Not specifically confirmed | May be captured under CDSA analog provisions; status unverifiedcitation needed |
| Australia | Not specifically confirmed | May be captured under analog provisions of the SUSMP; status unverifiedcitation needed |
The compound's scheduling preceded and likely contributed to market displacement toward newer, unscheduled synthetic cannabinoid analogs, continuing the cyclical pattern of scheduling followed by structural modification to evade controls.
references
- [1]
- [2]
- [3] ^abcdUchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2012) New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products — Forensic Toxicology doi:10.1007/s11419-012-0171-4
- [4] ^abcdShopan N, Scolnik D, Hassoun E, Firsow A, Volkov I, Glatstein M (2023) Acute intoxication caused by three common synthetic cannabinoids: The experience of a large, urban, tertiary care hospital — American Journal of Emergency Medicine doi:10.1016/j.ajem.2023.08.007
- [5] ^abcdTrexler KR, Vanegas SO, Poklis JL, Kinsey SG (2020) The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice — Drug and Alcohol Dependence doi:10.1016/j.drugalcdep.2020.108179
- [6] ^abcdeLam RPK, Tang MHY, Leung SC, Chong YK, Tsui MSH, Mak TWL (2017) Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations — Clinical Toxicology doi:10.1080/15563650.2017.1307385